<DOC>
	<DOCNO>NCT01083030</DOCNO>
	<brief_summary>The aim study correlate efficacy treatment proportion paclitaxel-dose supplied catheter . Forty-five patient treat paclitaxel-coated uncoated conventional balloon catheter randomize order 3 study center . Main inclusion criterion Rutherford class 2 - 5 , ≥70 % stenosis occlusion superficial femoral popliteal artery , main exclusion criterion relate use paclitaxel need follow-up examination . Either clinical angiographic follow-up examination plan 6 , 12 24 month follow intervention . Primary endpoint 6-month angiographic late lumen loss . Secondary endpoint angiographic clinical efficacy various safety criterion .</brief_summary>
	<brief_title>Paclitaxel-coated Balloons Femoral Indication Defeat Restenosis</brief_title>
	<detailed_description>Paclitaxel-coated balloon show reduce late lumen loss , restenosis rate need repeat target lesion revascularization compare conventional uncoated balloon catheter . The aim study correlate efficacy treatment proportion paclitaxel-dose supplied catheter . To end paclitaxel loss catheter introductory sheaths residual paclitaxel use balloon determine correlate individual data indicate inhibition neointimal proliferation . According study protocol 45 patient treat paclitaxel-coated uncoated conventional balloon catheter randomize order 3 study center . Main inclusion criterion Rutherford class 2 - 5 , ≥70 % stenosis occlusion superficial femoral popliteal artery , 3 30 cm length ; beyond common contraindication PTA main exclusion criterion relate use paclitaxel need follow-up examination . Patients blind treatment . Blinding investigator assignment patient treatment possible due difference appearance coat uncoated catheter . Either clinical angiographic follow-up examination plan 6 , 12 24 month follow intervention . Primary endpoint 6-month angiographic late lumen loss evaluate blinded independent core lab . Secondary endpoint interventional success rate , restenosis rate , minimal lumen diameter , target lesion revascularization , change Rutherford class , change ankle-brachial-index , major amputation , composite safety endpoint ( define MAE =death cause , target limb amputation , clinically / DUS driven TLR ) kinds serious adverse event possibly relate treatment .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Adult patient PAOD , Rutherford stage 25 , Occlusion stenosis &gt; 70 % diameter least 3 cm length superficial femoral artery and/ popliteal artery Acute thrombus aneurysm index limb/ vessel Doubts willingness capability patient allow follow examination</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>pAVK</keyword>
	<keyword>PTA</keyword>
	<keyword>drug coat balloon</keyword>
</DOC>